AU2003296875B2 - Treatment of infections and other disorders - Google Patents

Treatment of infections and other disorders Download PDF

Info

Publication number
AU2003296875B2
AU2003296875B2 AU2003296875A AU2003296875A AU2003296875B2 AU 2003296875 B2 AU2003296875 B2 AU 2003296875B2 AU 2003296875 A AU2003296875 A AU 2003296875A AU 2003296875 A AU2003296875 A AU 2003296875A AU 2003296875 B2 AU2003296875 B2 AU 2003296875B2
Authority
AU
Australia
Prior art keywords
polypeptide
infection
pulmonary
microbial
microbial infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003296875A
Other languages
English (en)
Other versions
AU2003296875A1 (en
Inventor
Jack Finkelstein Jr.
Allan L. Goldstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RegeneRx Biopharmaceuticals Inc
Original Assignee
RegeneRx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RegeneRx Biopharmaceuticals Inc filed Critical RegeneRx Biopharmaceuticals Inc
Publication of AU2003296875A1 publication Critical patent/AU2003296875A1/en
Application granted granted Critical
Publication of AU2003296875B2 publication Critical patent/AU2003296875B2/en
Priority to AU2008201749A priority Critical patent/AU2008201749B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2003296875A 2002-02-06 2003-02-06 Treatment of infections and other disorders Ceased AU2003296875B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008201749A AU2008201749B2 (en) 2002-02-06 2008-04-21 Treatment of Infections and Other Disorders

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35425002P 2002-02-06 2002-02-06
US60/354,250 2002-02-06
US42103802P 2002-10-25 2002-10-25
US60/421,038 2002-10-25
PCT/US2003/003455 WO2004035008A2 (en) 2002-02-06 2003-02-06 Treatment of infections and other disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008201749A Division AU2008201749B2 (en) 2002-02-06 2008-04-21 Treatment of Infections and Other Disorders

Publications (2)

Publication Number Publication Date
AU2003296875A1 AU2003296875A1 (en) 2004-05-04
AU2003296875B2 true AU2003296875B2 (en) 2008-01-24

Family

ID=32109894

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003296875A Ceased AU2003296875B2 (en) 2002-02-06 2003-02-06 Treatment of infections and other disorders

Country Status (6)

Country Link
US (2) US20060089310A1 (enExample)
EP (2) EP2266595A3 (enExample)
JP (1) JP2006507270A (enExample)
AU (1) AU2003296875B2 (enExample)
CA (1) CA2475053A1 (enExample)
WO (1) WO2004035008A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076254A2 (en) * 2005-01-11 2006-07-20 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing respiratory microbial infection of respiratory tissue
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
AU2011218617B2 (en) * 2004-05-12 2014-09-04 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat infections
CA2607686C (en) 2004-05-12 2014-11-04 Thomas P. Stossel Use of gelsolin to treat infections
KR100716119B1 (ko) * 2005-10-24 2007-05-10 (주)케어젠 모발 성장을 촉진하는 펩티드 및 이를 이용한 화장품
AU2007227613A1 (en) 2006-03-15 2007-09-27 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
EP2002258B1 (en) 2006-03-15 2017-09-27 The Brigham and Women's Hospital, Inc. Use of gelsolin to treat multiple sclerosis and to diagnose neurologic diseases
US8399412B2 (en) 2006-10-06 2013-03-19 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating NF-kappabeta or supressing NF-kappabeta-mediated actions
KR20100057050A (ko) * 2007-09-11 2010-05-28 몬도바이오테크 래보래토리즈 아게 치료제로서의 데슬로렐린 및 마스토파란의 용도
US20100210540A1 (en) * 2007-09-11 2010-08-19 Dorian Bevec Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
JP5778425B2 (ja) 2008-01-25 2015-09-16 ザ ジェネラル ホスピタル コーポレイション 腎不全におけるゲルソリンの診断的および治療的使用
MX2010010177A (es) * 2008-03-17 2012-08-23 Regenerx Biopharmaceuticals Fragmentos de beta timosina mejorada.
US8609604B2 (en) 2009-12-28 2013-12-17 N.V. Perricone Llc Methods of improving the appearance of aging skin
US8580742B2 (en) 2010-03-05 2013-11-12 N.V. Perricone Llc Topical glutathione formulations for menopausal skin
US20110160144A1 (en) * 2009-12-28 2011-06-30 Perricone Nicholas V Topical Acyl Glutathione Formulations
BR112013000923A2 (pt) * 2010-07-14 2016-05-17 Adistem Ltd método de tratamento de hiv ou aids
CN103724422B (zh) * 2014-01-13 2015-10-21 哈尔滨吉象隆生物技术有限公司 一种裂解胸腺素β4的方法
US10409955B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
EP3209803A4 (en) 2014-10-21 2018-06-13 Ubiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10793907B2 (en) 2014-10-21 2020-10-06 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US11783914B2 (en) 2014-10-21 2023-10-10 Psomagen, Inc. Method and system for panel characterizations
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US10789334B2 (en) 2014-10-21 2020-09-29 Psomagen, Inc. Method and system for microbial pharmacogenomics
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US9754080B2 (en) 2014-10-21 2017-09-05 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
US10346592B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
US10246753B2 (en) 2015-04-13 2019-04-02 uBiome, Inc. Method and system for characterizing mouth-associated conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297276A (en) * 1979-03-23 1981-10-27 Hoffman-La Roche Inc. Thymosin beta 3 and beta 4
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
WO1999049883A2 (en) * 1998-03-28 1999-10-07 The University Court Of The University Of Glasgow Oxidized thymosin beta 4
WO2000061901A1 (en) * 1999-04-14 2000-10-19 Southco, Inc. Crescent hinge

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2156735A1 (en) * 1993-02-22 1994-09-01 Ulrich-Christoph Von Arnim Pharmaceutical compositions for the treatment of inflammatory or immunological diseases and a method for the treatment of said diseases
PT1100529E (pt) * 1998-07-30 2005-10-31 Us Gov Health & Human Serv A timosina beta 4 promove a preparacao de feridas
AU2002336408B2 (en) * 2001-08-29 2006-12-21 Regenerx Biopharmaceuticals, Inc. Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives
KR102632066B1 (ko) 2015-07-30 2024-02-02 가부시키가이샤 한도오따이 에네루기 켄큐쇼 발광 장치의 제작 방법, 발광 장치, 모듈, 및 전자 기기

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297276A (en) * 1979-03-23 1981-10-27 Hoffman-La Roche Inc. Thymosin beta 3 and beta 4
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
WO1999049883A2 (en) * 1998-03-28 1999-10-07 The University Court Of The University Of Glasgow Oxidized thymosin beta 4
WO2000061901A1 (en) * 1999-04-14 2000-10-19 Southco, Inc. Crescent hinge

Also Published As

Publication number Publication date
AU2003296875A1 (en) 2004-05-04
EP2266595A2 (en) 2010-12-29
EP1497322A4 (en) 2006-11-08
CA2475053A1 (en) 2004-04-29
WO2004035008A3 (en) 2004-11-04
EP2266595A3 (en) 2011-07-06
US20110144020A1 (en) 2011-06-16
EP1497322A2 (en) 2005-01-19
JP2006507270A (ja) 2006-03-02
WO2004035008A2 (en) 2004-04-29
US20060089310A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
AU2003296875B2 (en) Treatment of infections and other disorders
JP2009046502A (ja) 皮膚状態の改善を促進するための組成物の製造のための、アミノ酸配列ｌｋｋｔｅｔを含む皮膚変性阻害ポリペプチドの使用
US20080051348A1 (en) Treatment of infections and other disorders
CA2593201C (en) Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease
AU2004308378B2 (en) Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent
AU2002309842B2 (en) Treating epidermlyosis bullosa with thymosin beta 4
AU2008201749B2 (en) Treatment of Infections and Other Disorders
US20060246057A1 (en) Treatment or prevention of damage due to radiation exposure
JP2007521336A5 (enExample)
AU2002309842A1 (en) Treating epidermlyosis bullosa with thymosin beta 4
HK1151729A (en) Treatment of infections and other disorders
AU2002213513A1 (en) Inhibition or reversal of skin aging by actin-sequestering peptides
US20040067227A1 (en) Inhibition or reversal of skin aging by actin-sequestering peptides
MXPA04007579A (es) Composiciones farmaceuticas para el tratamiento de infecciones y otros desordenes.
US20040170625A1 (en) Methods of treating Epidermolysis Bullosa and associated dermatological indications with thymosin beta 4, analogues, isoforms and other derivatives
WO2006076255A2 (en) Method of treating or preventing microbial eye infection
CZ159298A3 (cs) Farmaceutický prostředek
WO2006076254A2 (en) Method of treating or preventing respiratory microbial infection of respiratory tissue

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired